TARS

Tarsus Pharmaceuticals, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$76.89

Price (1 Year)

$90.78 $58.14

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %3.7 / %30
Non-compliant assets / Total market cap %16.2 / %30
Non-compliant revenue / Total income %2.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.

Website

Analysis (Turkish): TARS Hissesi Caiz mi, Helal mi? Tarsus Pharmaceuticals, Inc. Katılım Analizi